Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Jansen

Showing results (691-700 of 703) with videos related to

Pageof 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 10, 2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysisJudith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
International Journal of Cancer|July 10, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trialsLaurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, et al.
BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 25, 2022
Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With GoutNicholas A Sumpter, Riku Takei, Murray Cadzow, et al.
The Journal of Rheumatology|February 19, 2013
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteriaRebecca L Prowse, Nicola Dalbeth, Arthur Kavanaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery ProtocolLaurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided TreatmentLouisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, et al.
Annals of the Rheumatic Diseases|December 13, 2012
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritisMaša Umiċeviċ Mirkov, Jing Cui, Sita H Vermeulen, et al.
Annals of the Rheumatic Diseases|July 26, 2023
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition diseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2023
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition DiseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Pageof 71

Showing results (691-700 of 703) with videos related to

Sort By:
Pageof 71
European Journal of Cancer (Oxford, England : 1990)|May 10, 2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysisJudith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
International Journal of Cancer|July 10, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trialsLaurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, et al.
BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 25, 2022
Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With GoutNicholas A Sumpter, Riku Takei, Murray Cadzow, et al.
The Journal of Rheumatology|February 19, 2013
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteriaRebecca L Prowse, Nicola Dalbeth, Arthur Kavanaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery ProtocolLaurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided TreatmentLouisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, et al.
Annals of the Rheumatic Diseases|December 13, 2012
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritisMaša Umiċeviċ Mirkov, Jing Cui, Sita H Vermeulen, et al.
Annals of the Rheumatic Diseases|July 26, 2023
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition diseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2023
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition DiseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Pageof 71